Stem cells injected into ALS patients in first human trial
NCT ID NCT07118319
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether injecting lab-grown nerve cells (made from stem cells) into the spinal cord is safe for people with ALS, a fatal disease that destroys movement control. Twelve participants will receive the cells either once or four times over six months. The main goal is to check for side effects, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iPSC-derived motor neuron progenitor cells (XS228CN)
- What this could lead to
- If safe and effective, this could point toward a cell-replacement therapy to slow or halt ALS progression.
- What could go wrong
- This is a very early Phase 1 trial with only 12 participants, focused on safety. It may not show any benefit, and cell therapies carry risks like immune rejection or tumor formation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100191, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Custom-Made genetic drug slow ALS?
- Can a One-Time gene shot calm inflammation in ALS?
- Can filtering the blood slow ALS in people with a troubling antibody?
- Blood test may slash ALS diagnosis time from months to days
- Custom gene silencer takes aim at a rare form of ALS
- Could a gentle brain ZAP help ALS patients breathe easier?